The financing comes after the corporation received clearance from the US FDA for its patented device, intended for bedside neurosurgery. Credit: Sasin Tipchai from Pixabay.

Hubly Surgical has raised $3m in an oversubscribed Series Seed funding round for the advancement of its growth objectives.

The funding round comes after the corporation recently received clearance from the US Food and Drug Administration (FDA) for its Hubly Drill patented device, intended for bedside neurosurgery.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Most of the investment was made by the company’s commission-only distributor sales force, existing investors, neurosurgeons and physician-centric funds.

According to the company, the regulatory approval process ensures Hubly Drill’s safety and efficacy, providing investors with confidence in the corporation’s path towards financial growth and a positive impact on patients.

The funding will be utilised by the company for expanding its commercial launch to three additional US regions, as well as increasing access to the cranial drill product.

See Also:

The company also intends to use the investment for post-market clinical data collection and new product development initiatives in collaboration with Ontogen Medtech for addressing additional patient indications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Hubly founder and CEO Casey Qadir (m. Grage) said: “FDA clearance is our most significant milestone to date but it wouldn’t be as powerful without the resources to commercialise.

“I am honoured and thrilled to have solicited such strong support from our sales force, existing investors and the neurosurgeon users, all of whom share our vision for transforming neurosurgical procedures.

“With this investment, we are well-positioned to provide innovative solutions that improve surgical outcomes in all settings.”